Piramal Pharma Ltd

Wed 29/07/2026,11:9:59 | NSE : PPLPHARMA

₹196.673.24 (1.68%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 194.45

Previous Close

₹ 193.43

Volume

6761820

Mkt Cap ( Rs. Cr)

₹26183.62

High

₹ 201.00

Low

₹ 193.20

52 Week High

₹ 210.50

52 Week Low

₹ 132.30

Book Value Per Share

₹ 61.34

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Piramal Pharma Ltd

Your Vote -

Buy

64.37%

Hold

11.88%

Sell

23.75%

64.37%

261 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

15%

Sell Order Quantity

85%

Bid Price

Qty

196.54

40

197.00

49

197.00

135

197.00

75

196.00

107

Bid Total

350810

Bid Price

Qty

196.65

199

197.00

63

197.00

202

197.00

208

197.00

546

Bid Total

1993439

Option Chain

Analyzes market sentiment, predicts Piramal Pharma Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Piramal Pharma - Updates

    24 Jul 2026, 8:56PM Please refer attachment.

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Jul 2026, 1:00PM Piramal Pharma Limited has informed the Exchange about Schedule of meet

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 Jul 2026, 12:54PM Please find enclosed intimation of Analyst Meet scheduled to be held on 30th July 2026.

  • Piramal Pharma - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Conso

    20 Jul 2026, 12:34PM Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 ,inter alia, to consider and a

  • Piramal Pharma has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    17 Jul 2026, 1:40PM As of June 2026, 34.80% is owned by Indian Promoters, 64.72% by Public and 0.48% by Non Promoters-Non Public. <p align=justify> Institutional holds 27

  • Piramal Pharma - General Updates

    9 Jul 2026, 10:58AM Successful closure of US FDA Inspection at Piramal Pharma s manufacturing facility located at Sellersville (USA) facility

  • Piramal Pharma - Copy of Newspaper Publication

    4 Jul 2026, 1:01PM Newspaper Advertisement for dispatch of notice of the 6th Annual General Meeting ( AGM ) and E-Voting Information

  • Piramal Pharma - Updates

    3 Jul 2026, 5:21PM Business Responsibility & Sustainability Report for the financial year 2025-26

  • Piramal Pharma - Business Responsibility and Sustainability Reporting (BRSR)

    3 Jul 2026, 4:37PM Business Responsibility and Sustainability Reporting for the Financial Year 2025-26

  • Piramal Pharma - Reg. 34 (1) Annual Report.

    3 Jul 2026, 3:32PM Notice of the 6th Annual General Meeting and Annual Report for the financial year 2025-26

  • Piramal Pharma - Shareholders meeting

    3 Jul 2026, 3:21PM Notice of the 6th Annual General Meeting and Annual Report for the financial year 2025 26

  • Piramal Pharma - Notice Of The 6Th Annual General Meeting And Annual Report For The Financial Year 2025-26

    3 Jul 2026, 3:16PM Notice of the 6th Annual General Meeting and Annual Report for the financial year 2025-26

  • Piramal Pharma - Disclosure under SEBI Takeover Regulations

    29 Jun 2026, 7:45PM Ajay G. Piramal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial A

  • Piramal Pharma - Trading Window

    29 Jun 2026, 4:47PM Piramal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2

  • Piramal Pharma - News Verification

    23 Jun 2026, 4:38PM The Exchange has sought clarification from Piramal Pharma Limited with respect to recent news item captioned Piramal Pharma Share Price Spikes Over 10

  • Piramal Pharma - News Verification

    23 Jun 2026, 1:11PM The Exchange has sought clarification from Piramal Pharma Limited with respect to recent news item captioned Piramal Pharma Share Price Spikes Over 10

  • Piramal Pharma - Clarification On News Item Appearing On NDTV Profit Captioned - \Piramal Pharma Share Price Spikes Over 10%

    23 Jun 2026, 4:34PM Please refer attached file

  • Piramal Pharma - Clarification sought from Piramal Pharma Ltd

    23 Jun 2026, 1:26PM The Exchange has sought clarification from Piramal Pharma Ltd on June 23, 2026, with reference to news appeared in https://www.ndtvprofit.com dated Ju

  • Piramal Pharma - Copy of Newspaper Publication

    19 Jun 2026, 4:06PM Newspaper Advertisement for information regarding 6th Annual General Meeting of the Company

  • Piramal Pharma - ESOP/ESOS/ESPS

    5 Jun 2026, 5:48PM Piramal Pharma Limited has informed the Exchange regarding Allotment of 2100000 Shares.

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    5 Jun 2026, 5:27PM Please find enclosed intimation of allotment of ESOPs.

  • Piramal Pharma - Action(s) taken or orders passed

    3 Jun 2026, 11:05AM Permanent revocation of closure directions for Company s Dahej Site

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Jun 2026, 12:04PM Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Jun 2026, 11:59AM Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    19 May 2026, 2:08PM Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    19 May 2026, 2:05PM Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - General Updates

    18 May 2026, 11:45AM Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Successful closure of US FDA Inspecti

  • Piramal Pharma - General Updates

    10 May 2026, 10:26PM Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    4 May 2026, 3:22PM Intimation of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 May 2026, 3:16PM Intimation of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Apr 2026, 2:46PM Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    30 Apr 2026, 2:53PM Transcript of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026

  • Piramal Pharma - General Updates

    29 Apr 2026, 4:51PM Contact details of Key Managerial Personnel as required under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulatio

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Apr 2026, 4:45PM Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026

  • Piramal Pharma - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Apr 2026, 4:33PM Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026

  • Piramal Pharma - Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligati

    29 Apr 2026, 5:00PM Please refer attached file

  • Piramal Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    29 Apr 2026, 4:52PM Audio Recording of Conference Call on the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March, 2026

  • Piramal Pharma

    21 Mar 2025 , 10:19AM Piramal Pharma arm gets market authorization for Neoatrico from United Kingdom’s Medicines and Healthcare Products Regulatory Agency. Neoatrico is a paediatric solution used in treatment for hypotension in neonates, infants, and children. Positive

  • Piramal Pharma

    19 Feb 2025 , 10:26AM Piramal Pharma: The US FDA issued Form 483 with six observations for the company’s Turbhe facility.

  • Piramal Pharma

    23 Jan 2025 , 9:39AM Piramal Critical Care launches Chlorpromazine Hydrochloride in US. With this launch, company continues to expand their generic injectables portfolio.

  • Piramal Pharma

    18 Apr 2024 , 11:50AM The US FDA had Inspected Piramal Pharma’s manufacturing facility located at Riverview, USA and has issued an Establishment Inspection Report (EIR) for the said manufacturing facility and the inspection has now been successfully closed by the US FDA. Positive

  • Piramal Pharma

    26 Feb 2024 , 12:37PM The US FDA conducted a Pre-Approval Inspection (PAI) inspection of Piramal Pharma Limited's Lexington (USA) facility from 20th February, 2024 to 23rd February, 2024 for one of the product expected to be manufactured at this facility. On conclusion of the inspection, a Form-483 was issued with 2 observations. The observations does not pose any risk to site’s compliance standards or its business continuity. The Company is preparing a detailed response to said observations, which will be submitted to the US FDA within stipulated timelines. (Positive).

  • Piramal Pharma

    17 Jan 2024 , 9:37AM Piramal Critical Care division has announced the launch of a new 10mg/10mL (1 mg/mL) concentration of Zinc Sulfate for Injection USP in the United States of America. The launch will enable PCC to further expand their zinc sulphate existing product line and overall generic injectable portfolio. Positive
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Piramal Pharma Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 8851.02 8674.47 7863.96 6889.07 6168.87
Liabilities 8851.02 8674.47 7863.96 6889.07 6168.87
Equity 1327.16 1324.35 1322.95 1193.32 1185.91
Gross Profit 642 1040.44 617.92 97.53 397.3
Net Profit 700.01 691.4 391.22 69.5 343.05
Cash From Operating Activities 1328.12 548.77 358.29 71.52 255.2
NPM(%) 14.63 13.08 8.91 2.01 11.08
Revenue 4782.01 5285.71 4390.11 3443.22 3094.95
Expenses 4140.01 4245.27 3772.19 3345.69 2697.65
ROE(%) 8.57 8.46 4.79 0.85 4.2

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
16 Jul 2025 0.14 1.4 0 219.04
12 Jul 2024 0.11 1.1 0 150.45

Peers

Other companies within the same industry or sector that are comparable to Piramal Pharma Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 689.50 0.42 0.00 110.38 -26.19 0.73
Lotus Eye Hospital and Institute Ltd 119.61 0.88 3987.00 402.20 0.39 0.00
Vaishali Pharma Ltd 7.50 1.49 25.00 2523.14 15.42 0.00
Astec Lifesciences Ltd 651.70 0.35 0.00 430.94 -363.14 0.00

Company Info

Our Company was incorporated on March 4, 2020 at Mumbai as a public limited company under the Companies Act and was granted the certificate of incorporation by the RoC.Major events and milestones:2020-Acquired pharmaceutical business from PEL-20% Strategic Growth Investment by Carlyle-Increased stake to 100% in CCPL2021Acquisition of HPPL2022-Acquisition of minority stake in Yapan Bio Private Limited-Composite Scheme of Arrangement under the provisions of section 230 to 232 and other applicable provisions of the Companies Act, 2013 amongst PEL, the Company, CCPL, HPPL, PFPL and their respective shareholders and creditors, sanctioned by the NCLT on August 12, 2022. Pursuant to the Scheme, Demerged Undertaking of PEL, transferred and vested into the Company. 2020 -Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals. -Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs. -Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish -Piramal Critical Care Announces Strategic Partnership with US-Based Pharmaceutical Outsourcing Facility Medivant Healthcare 2021 -Piramal Pharma Solutions Announces Winner of its Inaugural Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc. -Piramal Pharma Limited's Consumer Products Division Launches `i-feelr' 2022 -Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Launches ADCelerate, a Rapid, Integrated Approach to Taking ADCs to IND. -Piramal Pharma Solutions Holds Grand Opening Ceremony for New API Plant at Aurora, Canada Manufacturing Site. -Piramal Pharma Solutions New API Plant in Canada Goes Online; Initial Production Runs Successfully Completed. 2023 -Company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share. 2024 - Piramal Pharma Limited (PPL) launches new campaign for Polycrol with Brand Ambassador Jisshu Sengupta. -Piramal Pharma Limited ( the Company ) forays into men's grooming market with the launch of BOHEM. 2025 -Piramal Critical Care Announces U.S. Launch of ChlorpromazineHydrochloride for Injection, USP.

Our Company was incorporated on March 4, 2020 at Mumbai as a public limited company under the Companies Act and was granted the certificate of incorporation by the RoC.Major events and milestones:2020-Acquired pharmaceutical business from PEL-20% Strategic Growth Investment by Carlyle-Increased stake to 100% in CCPL2021Acquisition of HPPL2022-Acquisition of minority stake in Yapan Bio Private Limited-Composite Scheme of Arrangement under the provisions of section 230 to 232 and other applicable provisions of the Companies Act, 2013 amongst PEL, the Company, CCPL, HPPL, PFPL and their respective shareholders and creditors, sanctioned by the NCLT on August 12, 2022. Pursuant to the Scheme, Demerged Undertaking of PEL, transferred and vested into the Company. 2020 -Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals. -Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs. -Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish -Piramal Critical Care Announces Strategic Partnership with US-Based Pharmaceutical Outsourcing Facility Medivant Healthcare 2021 -Piramal Pharma Solutions Announces Winner of its Inaugural Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc. -Piramal Pharma Limited's Consumer Products Division Launches `i-feelr' 2022 -Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity. -Piramal Pharma Solutions Launches ADCelerate, a Rapid, Integrated Approach to Taking ADCs to IND. -Piramal Pharma Solutions Holds Grand Opening Ceremony for New API Plant at Aurora, Canada Manufacturing Site. -Piramal Pharma Solutions New API Plant in Canada Goes Online; Initial Production Runs Successfully Completed. 2023 -Company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share. 2024 - Piramal Pharma Limited (PPL) launches new campaign for Polycrol with Brand Ambassador Jisshu Sengupta. -Piramal Pharma Limited ( the Company ) forays into men's grooming market with the launch of BOHEM. 2025 -Piramal Critical Care Announces U.S. Launch of ChlorpromazineHydrochloride for Injection, USP.

Parent Organisation

Piramal Pharma Ltd.

Founded

04/03/2020

Managing Director

NSE Symbol

PPLPHARMAEQ

FAQ